ClinicalTrialsFinder
RecruitingPhase 1NCT05544019

Study of SGR-1505 in Mature B-Cell Neoplasms

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies

Sponsor

Schrödinger, Inc.

Enrollment

98 participants

Start Date

Apr 10, 2023

Study Type

INTERVENTIONAL

Conditions

High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin LymphomaMantle Cell LymphomaFollicular LymphomaPlasmablastic LymphomaBurkitt LymphomaSplenic Marginal Zone LymphomaNodal Marginal Zone LymphomaMature B-Cell NeoplasmWaldenstrom MacroglobulinemiaLymphoplasmacytic LymphomaPrimary Mediastinal Large B Cell LymphomaDLBCLDLBCL Germinal Center B-Cell TypeALK-Positive Large B-Cell LymphomaMALT LymphomaPediatric-Type Follicular LymphomaIRF4 Gene RearrangementEBV-Positive DLBCL, NosPrimary Cutaneous Follicle Center LymphomaPrimary Effusion LymphomaT-Cell/Histiocyte Rich LymphomaPrimary Cutaneous Diffuse Large B-Cell LymphomaHHV8-Positive DLBCL, NosDuodenal-Type Follicular Lymphoma

Summary

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a new drug called SGR-1505 for people with certain types of blood cancers that affect B-cells — a type of white blood cell. Researchers want to see if the drug is safe and effective. **You may be eligible if...** - You have been diagnosed with a mature B-cell blood cancer (such as certain types of lymphoma or leukemia) - Your disease can be measured or detected and you need treatment - You are generally in good physical condition (able to care for yourself and do light activity) - You have a life expectancy of at least 12 weeks **You may NOT be eligible if...** - You need immediate aggressive treatment to reduce cancer fast - You have had another cancer in the last 2 years - You are allergic to SGR-1505 - Your cancer has spread to your brain or spinal cord and is causing symptoms - You have serious untreated medical conditions Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSGR-1505

SGR-1505 will be administered orally.

Locations(36)

Banner Health - MD Anderson Cancer Center

Gilbert, Arizona, United States

Christiana Care Hospital - Helen F Graham Cancer Center

Newark, Delaware, United States

Napa Research

Pompano Beach, Florida, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Regional Cancer Care Associates

Hackensack, New Jersey, United States

Roswell Park Comprehensive Cancer Center

Buffalo, New York, United States

Weill Cornell

New York, New York, United States

Montefiore Medical Center

The Bronx, New York, United States

Duke University

Durham, North Carolina, United States

Gabrail Cancer & Research Center

Canton, Ohio, United States

The Ohio State University - The James Cancer Hospital

Columbus, Ohio, United States

Oregon Health and Science University - Knight Cancer Institute

Portland, Oregon, United States

Rhode Island Hospital

Providence, Rhode Island, United States

University of Texas Southwestern

Dallas, Texas, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

AP-HP Hôpital Henri-Mondor

Créteil, France

Institut Gustave Roussy

Villejuif, France

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e C. Arrigo - Presidio Ospedaliero SS Antonio e Biagio e Cesare Arrigo, Ospedale Civile

Alessandria, Italy

ASST Grande Ospedale Metropolitano Niguarda

Milan, Italy

IRCCS Ospedale San Raffaele

Milan, Italy

AOU Citta della Salute e della Scienza di Torino - Ospedale le Molinette

Torino, Italy

Azienda Ospedaliera - Universitaria Integrata di Verona - Ospedale Borgo Roma

Verona, Italy

Institute of Oncology, ARENSIA Exploratory Medicine

Chisinau, Moldova

Uniwersyteckie Centrum Kliniczne, Osrodek Badan Klinicznych Wczesnych Faz

Gdansk, Poland

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi

Lodz, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie

Warsaw, Poland

ARENSIA Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti

Bucharest, Romania

ARENSIA Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca

Cluj-Napoca, Romania

Institut Catala d'Oncologia - L'Hospitalet

Barcelona, Spain

Hospital Universitario Quironsalud Madrid

Madrid, Spain

START Madrid - CIOCC

Madrid, Spain

START Madrid - Hospital Fundacion Jimenez Diaz

Madrid, Spain

Clinica Universidad de Navarra - Pamplona

Pamplona, Spain

Hospital Clinico Universitario de Salamanca

Salamanca, Spain

ARENSIA Research Clinic at Harmony Health Clinic

Kyiv, Ukraine

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05544019

Related Trials

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

NCT04269902629 locations

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT0509142431 locations

Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer

NCT000065181 location

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

NCT009235071 location

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

NCT072499052 locations